| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-05 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |